publication venue for
- Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. 23:231-269. 2015
- Pathophysiology, diagnosis, and management of hepatic encephalopathy. 22:319-326. 2014
- Pharmacology of intra-articular triamcinolone. 22:201-217. 2014
- Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?. 21:125-127. 2013
- The pharmacological modulation of allergen-induced asthma. 21:113-124. 2013
- The musculoskeletal abnormalities of the Similaun Iceman (“ÖTZI”): clues to chronic pain and possible treatments. 21:11-20. 2013
- The biological activity of auranofin: implications for novel treatment of diseases. 20:297-306. 2012
- The end of evidence-based medicine?. 20:187-193. 2012
- Obesity and knee osteoarthritis. 20:53-58. 2012
- Commentary Re: Botox Article by Berger & Knoll IPH 19(5):243–244 on “The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis”. 20:51-51. 2012
- Drug-resistant tuberculosis: an insurmountable epidemic?. 19:131-137. 2011
- Paul-Peter Tak (ed): New Therapeutic Targets in Rheumatoid Arthritis (Series: PIR—Progress in Inflammation Research). 19:53-54. 2011
- The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. 19:21-34. 2011
- Concerning: “The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy” by Peter O. Behan and Abhijit Chaudhuri. 18:263-263. 2010
- Analgesic targets: today and tomorrow. 17:151-161. 2009
- Therapeutic transcranial magnetic stimulation in migraine and its implications for a neuroinflammatory hypothesis. 17:68-75. 2009
- The clinical assessment of transitional vertebrae and back pain. 16:278-283. 2008
- Clinical pharmacology of gold. 16:112-125. 2008
- Management of chronic musculoskeletal pain in the Elderly: Opinions on oral medication use. 16:53-75. 2008
- The use of NSAIDs in rheumatic disorders 2005: a global perspective. 13:343-370. 2005
- Osteoarthritis: symptoms, signs and source of pain. 12:3-31. 2004
- Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?. 11:337-354. 2003
- History and current status of osteoarthritis in the population. 11:301-316. 2003
- Coronary artery disease, inflammation and the ghost of John Hunter. 11:195-201. 2003
- A clinician’s view of strategies for preventing NSAID-induced gastrointestinal ulcers. 4:17-30. 1996
- Effects of non-steroidal anti-inflammatory drugs on prostaglandin h synthase isoenzyme 2 (cyclo-oxygenase 2) production by porcine gastric mucosa in organ culture. 3:299-310. 1995